| Author |
Title |
JournalName |
Year D |
| Click on Column Headers to Re-Sort The Current List |
| McKenney JD, Glennon RA |
TFMPP May Produce its Stimulus Effects Via a 5-HT1B Mechanism |
Pharmacology Biochem... |
1986 |
| Glennon RA |
Discriminative stimulus properties of the serotonergic agent 1-(2,5-di... |
Life Sci |
1986 |
| Glennon RA |
Discriminative stimulus properties of the serotonergic agent 1-(2,5-di... |
Life Sci |
1986 |
| Schechter MD |
Use of TFMPP stimulus properties as a model of 5-HT1B receptor activat... |
Pharmacol Biochem Be... |
1988 |
| Frances H |
Psychopharmacological profile of 1-(m-(trifluoromethyl) phenyl) pipera... |
Pharmacol Biochem Be... |
1988 |
| Schechter MD |
Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetami... |
Pharmacol Biochem Be... |
1989 |
| Appel JB, Callahan PM |
Involvement of 5-HT receptor subtypes in the discriminative stimulus p... |
Eur J Pharmacol |
1989 |
| Arnt J, Hyttel J |
Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2... |
Eur J Pharmacol |
1989 |
| Klodzinska A, Jaros T, Ch... |
Exploratory hypoactivity induced by m-trifluoromethylphenylpiperazine ... |
J Neural Transm Park... |
1989 |
| Chaouloff F, Laude D, Bau... |
Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5... |
Eur J Pharmacol |
1990 |
| Winslow JT, Insel TR |
Serotonergic modulation of the rat pup ultrasonic isolation call: stud... |
Psychopharmacology (... |
1991 |
| Boja JW, Schechter MD |
Possible serotonergic and dopaminergic mediation of the N-ethyl-3,4-me... |
Eur J Pharmacol |
1991 |
| Herndon JL, Pierson ME, G... |
Mechanistic investigation of the stimulus properties of 1-(3-trifluoro... |
Pharmacol Biochem Be... |
1992 |
| Schechter MD, Gordon TL |
Comparison of the behavioral effects of ibogaine from three sources: m... |
Eur J Pharmacol |
1993 |
| Schechter MD |
Serotonergic mediation of fenfluramine discriminative stimuli in fawn-... |
Life Sci |
1997 |
| de Boer D, Bosman IJ, Hid... |
Piperazine-like compounds: a new group of designer drugs-of-abuse on t... |
Forensic Sci Int |
2001 |
| Peters FT, Schaefer S, St... |
Screening for and validated quantification of amphetamines and of amph... |
J Mass Spectrom |
2003 |
| Staack RF, Fritschi G, Ma... |
New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas ... |
J Mass Spectrom |
2003 |
| Maurer HH, Kraemer T, Spr... |
Chemistry, pharmacology, toxicology, and hepatic metabolism of designe... |
Ther Drug Monit |
2004 |
| Fantegrossi WE, Winger G,... |
Reinforcing and discriminative stimulus effects of 1-benzylpiperazine ... |
Drug Alcohol Depend |
2005 |
| Baumann MH, Clark RD, Bud... |
N-substituted piperazines abused by humans mimic the molecular mechani... |
Neuropsychopharmacol... |
2005 |
| Staack RF, Maurer HH |
Metabolism of designer drugs of abuse |
Curr Drug Metab |
2005 |
| Russell B |
Party pills - how little is known? |
New Zealand Family P... |
2006 |
| Wood DM, Button J, Lidder... |
Dissociative and sympathomimetic toxicity associated with recreational... |
J Med Toxicol |
2008 |
| Lin JC, Jan RK, Lee H, Je... |
Determining the subjective and physiological effects of BZP combined w... |
Psychopharmacology B... |
2010 |
| Maskell PD, De Paoli G, S... |
Mephedrone (4-methylmethcathinone)-related deaths |
J Anal Toxicol |
2011 |
| Elliott S |
Current awareness of piperazines: pharmacology and toxicology |
Drug Test Anal |
2011 |
| Bassindale T |
Benzylpiperazine: the New Zealand legal perspective |
Drug Test Anal |
2011 |
| Arbo MD, Bastos ML, Carmo... |
Piperazine compounds as drugs of abuse |
Drug Alcohol Depend |
2011 |
